Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
B1- FY26 MCKESSON CONTRACT MEDICATION is a federal award for Fci Tallahassee held by Mckesson Corp. Estimated value $495K ($420K obligated). Current period of performance ends Aug 31, 2026. Place of performance: IRVING TX.
Recompete timing
PublicCurrent PoP ends Aug 31, 2026 (11 days remaining). Agencies typically plan 12–18 months ahead — at 0.4 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordMckesson Corp — $32.0B obligated across 6,790 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 15B31426F00000053?
15B31426F00000053 (B1- fy26 mckesson contract medication) is a Fci Tallahassee award with a potential value of $495K, currently held by Mckesson Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 15B31426F00000053?
Fci Tallahassee awarded 15B31426F00000053 to Mckesson Corp (potential $495K).
Who is the incumbent on 15B31426F00000053?
Mckesson Corp is the incumbent with $32.0B across 6790 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2026.
When does Mckesson Corp’s 15B31426F00000053 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.